Nuvalent Inc
NUVL77.160USD
-0.600-0.77%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
5.54BCap. mercado
PérdidaP/E TTM
Más Datos de Nuvalent Inc Compañía
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Información de la empresa
Símbolo de cotizaciónNUVL
Nombre de la empresaNuvalent Inc
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoDr. James R. (Jim) Porter, Ph.D.
Número de empleados142
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 29
DirecciónOne Broadway, 14Th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono18573577000
Sitio Webhttps://www.nuvalent.com/
Símbolo de cotizaciónNUVL
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoDr. James R. (Jim) Porter, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
Accionistas
Accionistas
Proporción
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
48.82%
Investment Advisor
35.80%
Investment Advisor/Hedge Fund
19.30%
Individual Investor
2.87%
Private Equity
2.46%
Research Firm
1.99%
Venture Capital
0.77%
Sovereign Wealth Fund
0.48%
Pension Fund
0.25%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
438
74.96M
112.94%
-1.46M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
2023Q2
230
58.54M
113.63%
-2.82M
2023Q1
202
57.17M
111.42%
-2.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Deerfield Management Company, L.P.
17.99M
27.11%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
9.70M
14.61%
+99.92K
+1.04%
Mar 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.94%
-93.95K
-1.75%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
6.68%
-60.03K
-1.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.73M
4.11%
-65.91K
-2.36%
Mar 31, 2025
Commodore Capital LP
1.85M
2.79%
+233.40K
+14.39%
Mar 31, 2025
Shair (Matthew)
1.64M
2.48%
+2.65K
+0.16%
Jun 18, 2025
Perceptive Advisors LLC
1.63M
2.46%
-986.01K
-37.63%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
1.45M
2.18%
--
--
Mar 31, 2025
Wellington Management Company, LLP
1.44M
2.17%
+157.81K
+12.28%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Tema Oncology ETF
3.99%
ALPS Medical Breakthroughs ETF
3.42%
Global X Guru Index ETF
1.27%
SPDR S&P Biotech ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
ProShares Ultra Nasdaq Biotechnology
0.56%
Invesco Nasdaq Biotechnology ETF
0.56%
iShares Health Innovation Active ETF
0.54%
Direxion Daily S&P Biotech Bull 3X Shares
0.53%
iShares Biotechnology ETF
0.35%
Ver más
Tema Oncology ETF
Proporción3.99%
ALPS Medical Breakthroughs ETF
Proporción3.42%
Global X Guru Index ETF
Proporción1.27%
SPDR S&P Biotech ETF
Proporción0.93%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.88%
ProShares Ultra Nasdaq Biotechnology
Proporción0.56%
Invesco Nasdaq Biotechnology ETF
Proporción0.56%
iShares Health Innovation Active ETF
Proporción0.54%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.53%
iShares Biotechnology ETF
Proporción0.35%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
